[A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine].

A controlled clinical trial, corresponding to stage 2, was conducted in a population of sound adult males aged 18-23 to evaluate the immunogenicity of 5 schedules of Cuban vaccine against hepatitis B (Heberbiovac-HB [correction of Cheberbiovac-HB]). 5 groups were studied: I (control group 0, 1 and 6 months), II (0 and 2 months), III (0 and 4 months), IV (0 and 6 months), and V (0 and 8 months). The results showed no significant differences as regards the percentage of seroprotection of any of the groups of 2 doses compared with the control of 3 doses. It is concluded that between the first and the second dose there may be a period of time from 2 to 6 months with no need to reinitiate the schedule. This information will serve as a basis for a population based study to determine which schedule is the best to be used.